Kornimate/medical-research-clean huggingface dataset:
wecanmanage. an mhealth self-management tool

Conditions: Breast Cancer; Head and Neck Cancer; Sarcoma

Summary: examine the feasibility, acceptability, user satisfaction, and response patterns and preliminary efficacy on targeted patient reported outcomes. using a pre-post, single arm feasibility design with cancer survivors with disabilities

examine the feasibility, acceptability, user satisfaction, and response patterns and preliminary efficacy on targeted patient reported outcomes. using a pre-post, single arm feasibility design with cancer survivors with disabilities, we will collect data on the wecanmanage app delivered self-management intervention's feasibility, acceptability, user satisfaction as well as response patterns and preliminary efficacy on targeted patient reported outcomes.

Eligibility criteria:
inclusion criteria: usability testing of the wecanmanage high fidelity prototype * age 18 or older * diagnosis of breast cancer, head and neck cancer or sarcoma * completion of active treatment * self-identify as a person with a disability according to the americans with disabilities .act and the american community survey 6-disability questions * able to understand and communicate in english * medically stable enough to participate in two data collection sessions totaling 2 hours evaluation of the wecanmanage app * age 18 or older * diagnosis of breast cancer, head and neck cancer or sarcoma * completion of primary (i.e. surgery, chemotherapy, and/or radiation); may still be under-going endocrine or hormone therapies * self-identify as experiencing disabling after-effects of cancer and its treatment according to the americans with disabilities act and the american community survey 6-disability questions * able to read, understand and communicate in english * ownership of a smartphone, tablet, or personal computer. * internet access exclusion criteria: usability testing of the wecanmanage high fidelity prototype * no diagnosis of breast cancer, head and neck cancer or sarcoma * in active treatment * does not self-identify as a person with a disability according to the americans with disabilities act and the american community survey 6-disability questions * not able to understand and communicate in english * not medically stable enough to participate in two data collection sessions totaling 2 hours evaluation of the wecanmanage app * age 17 or younger * no diagnosis of breast cancer, head and neck cancer or sarcoma * in active treatment * does not self-identify as experiencing long-term effects of cancer and its treatment according to the americans with disabilities act and the american community survey 6-disability questions * not able to read, understand, and communicate in english * does not have access to internet enabled smartphone, tablet, or personal computer * does not have access to the internet
safety and efficacy of different antiviral regimens for hepatitis c virus relapse

Conditions: Hepatitis C; Relapse; Antivirals

Summary: the primary goal of hepatitis c virus (hcv) direct acting antivirals (daas) is to achieve undetectable hcv rna in the blood. a response that should be maintained for at least 12 weeks from completion of therapy. this is called sustained virological response (svr) which corresponds to cure of hcv infection as risk of later relapse is very small. svr is important to achieve improvement in liver necroinflammation and fibrosis and to decrease complications of cirrhosis. failing to achieve svr after treatment requires another regimen for these experienced patients. real-world data are always needed to evaluate and improve our practices. here investigators aim to assess tolerability and efficacy of different regimens used for management of genotype 4 hcv relapse.


Eligibility criteria:
inclusion criteria: * all patients with hcv relapse after sofosbuvir plus either non-structural protein 5 a (ns5a) or protease inhibitor. exclusion criteria: * no exclusion criteria
3d geplante osteosynthesen mit patientenspezifischen zielvorrichtungen

Conditions: Fracture of Humerus; Fracture of Ulna Radius; Fracture of Clavicle; Fracture of Hand; Fracture of Pelvis; Fracture of Femur; Fracture of Tibia Fibula; Fracture of Skull

Summary: goal of this study is to evaluate the accuracy of 3d computer-planned fracture fixation with patient-specific instruments for clavicle, upper extremity, lower extremity and pelvis fractures compared with the standard procedure of fracture fixation.

the research hypothesis is: the medical product permits the fracture fixation of clavicle, upper extremity, lower extremity and pelvis fractures to be more accurate compared with standard procedures of fracture fixation. accuracy is evaluated by calculating translation and rotation comparing the postoperative 3d model versus the preoperative 3d plan. secondary outcome is an assessment of the surgical outcome using validated outcome instruments for each fractured body part like "patient related wrist evaluation" (prwe) scores for distal radial fractures, as well as evaluation of range of motion.

Eligibility criteria:
inclusion criteria: * fracture of clavicle, upper extremity, lower extremity or pelvis,tibia, fibula,femur, with indication for fracture fixation * clinical indication for a computed tomography of the fractured bone * \>18 years of age * patient is able to give informed consent exclusion criteria: * pregnancy or nursing women * non-compliance of the patient to follow the clinical study protocol, drug abuse or alcohol abuse * participation in a different clinical trial within the last 30 days before inclusion or during the study * allergy to polyamid pa 2200 * no available technique for fracture fixation which could be performed, in case of applying the medical device is not possible. * applying the medical device is not possible, because of technical or anatomical reasons. * other clinical significant accompanying symptoms (tumor, infection)
study to evaluate beta cell function and glycemic outcome by intensive insulin therapy

Conditions: Type 2 Diabetes Mellitus; Pancreatic Beta Cell Function; Glucotoxicity

Summary: this randomized controlled prospective study aims to evaluate the efficacy of intensive insulin therapy for long term glycemic control and improvement or preservation of beta cell function in newly diagnosed type 2 diabetes patients.

type 2 diabetes is associated with beta cell dysfunction and insulin action at diagnosis of diabetes. although the relative importance of these two alterations is controversial, growing evidence is swinging to the concept that there is no hyperglycemia without β-cell dysfunction. also there is agreement that deterioration of glucose tolerance over time is associated with a progressive decrease of beta cell function. beside the role of genetic factor, the continuous decline in β-cell function is affected by glucotoxicity generated by hyperglycemia and lipotoxicity due to high fatty acid. a vicious cycle of hyperglycemia per se further impairs and may destroy β-cell. recently, many reports have shown that early intensive glycemic control plays a role in the prevention of progressive ß-cell function and worsening of diabetes. some studies have shown that early intensive insulin therapy(iit) to achieve near normoglycemia in new onset type 2 diabetes gives short term and long term improvement in glycemic control after discontinuation of insulin. it is suggested that long term glycemic control is associated with improvement of β-cell function. in the unpublished previous pilot study, the investigators found that early intensive insulin therapy using multiple daily injection (mdi) or daily twice injection in newly diagnosed type 2 diabetes can significantly improve the beta cell function and facilitate further long term glycemic control. to establish the effectiveness of intensive insulin therapy for long term glycemic control and improvement of β-cell function, the investigators will perform a randomized controlled prospective study in newly diagnosed type 2 diabetes in korea.

Eligibility criteria:
inclusion criteria: * newly diagnosed drug naïve type 2 diabetic patient with typical diabetic symptom (polydipsia, polyuria, unexplained weight loss) within recent 1 year * initial hba1c : 8.0 % ≤ hba1c \< 12.0% exclusion criteria: * known contraindication to insulin glargine, insulin glulisine, metformin, glimepiride * patients with proliferative diabetic retinopathy * severe liver disease or ast, alt ≥ 2.5 x uln * history of lactic acidosis * unstable or severe angina * congestive heart failure * chronic disease treated with continuous corticosteroid therapy * diagnosis of cancer * positive urine pregnancy test or plan to become pregnant during the clinical trial

Keywords: type 2 diabetes mellitus intensive insulin therapy
the effect of therapeutic play on pain, fear and emotional indicator

Conditions: Hydrotherapy

Summary: this study was planned to determine the effect of therapeutic play and preparation for hydrotherapy treatment on pain, fear and emotional indicator levels in children with burn injuries. it is an experimental randomized controlled study. the population of the research will be children between the ages of 3-6 who are hospitalized in the pediatric burn intensive care unit. as a result of the power analysis using the g\*power 3.0.10 program, at least 52 children in total (control group 26, therapeutic play group 26) with 50% power, 0.05 alpha margin of error, 0.80 beta margin of error and 20% effect size. was determined to be included in the study. however, considering the case losses, the number of children to be included in the study was determined as 64 by increasing the sample size by 20%. the data will be collected between the dates to be determined by the researcher after obtaining the ethics committee approval and written permission from the institution where the research will be conducted. introductory information form, flacc pain scale, child fear scale and child emotional indicators scale will be used to collect research data. the research will be conducted with the children of parents who agreed to participate in the study. there are two groups, the control group and the experimental group. while the routine practice of the clinic will be applied to the control group, creative therapeutic games will be played to the experimental group together with the routine practice. children will be stratified according to their pain scores, fear scores and burn depth (degree) and will be assigned to an equal number of children in each group using the blocking method. before the procedure, the introductory information form will be filled in by the researcher in line with the patient file and parent information. after parents are informed about which group the child is in, their written consent will be obtained.


Eligibility criteria:
inclusion criteria: * the child is between 3-6 years old * the child is receiving the first hydrotherapy treatment in the clinic. * presence of second and/or third degree superficial and/or deep burns * volunteering of the child and family to participate in the research * the child was given analgesics half an hour before the procedure. * no simultaneous debridement during hydrotherapy * burn width between 20%-70% exclusion criteria: * the child is younger than 3 years old, over 6 years old * presence of any other chronic disease other than burns * the child is receiving mechanical ventilator support. * having a trecheostomy done to the child * the child has been given sedative medication in the last 8 hours. * having a companion other than mother or father * hydrotherapy treatment takes less than 30 minutes, more than 45 minutes * the child does not want to play

Keywords: hyrotherapy therapeutic game child
body weight supported treadmill training vs. overground walking training in persons with chronic stroke

Conditions: Stroke; Difficulty Walking

Summary: the purpose of this study is to compare two different walking training programs for persons with chronic stroke.

body weight supported treadmill training (bwstt) and overground walking training (owt) are two interventions commonly applied for enhancing gait and balance in patients with chronic stroke. bwstt and owt are often used by clinicians separately or in tandem. while various aspects of the two interventions have been investigated in the past, limited research has been conducted to compare the effects of the two interventions in patients with chronic stroke. longer training durations may not always be feasible due to limited reimbursement options, lack of clinic accessibility, or transportation restrictions for patients with chronic deficits following stroke. a short burst of training consisting of a ''booster''-like protocol may provide a convenient option for some patients with chronic stroke to improve necessary functional skills in a short period of time. the primary purpose of this pilot study is to compare walking speed immediately and 3-months after a short-burst of body-weight support treadmill training (bwstt) or overground walking training (owt) for adults with chronic stroke. twenty participants with chronic stroke will be recruited and screened to determine eligibility for the study. participants will be randomly assigned to either bwstt or owt for 30 minutes, 5 days per week for 2 weeks. outcome measures will include assessments of gait speed, endurance, walking pattern, fear of falling, balance confidence, anxiety, and activity and participation in daily life. outcomes will be tested prior to (pre-test) and immediately after (post-test) the assigned intervention and again 3-months after completing the intervention (retention).

Eligibility criteria:
inclusion criteria: * minimum of 6 months post-stroke * single episode of stroke * between the ages of 21-80 * able to walk with or without the use of an assistive device or orthoses * able to ambulate at a self-selected gait speed \< 0.8 m/s as determined by the 10-meter comfortable walk test * medically stable with a physician release stating approval to enter an exercise program * able to follow at least two-step verbal instructions * available for the entire period of the study * able to travel to and from research measurement and intervention sessions exclusion criteria: * currently receiving physical therapy services * co-morbidities or pre-existing cardiovascular conditions that would prohibit gait training and exercise * pre-existing neurological or current musculoskeletal conditions that would limit gait ability separate from the effects of stroke * complications from other health conditions that could influence walking * currently known to be pregnant

Keywords: chronic stroke walking training rehabilitation body weight supported treadmill training physical therapy balance
prediction of hypotension during beach chair position using pleth variability index

Conditions: Hypotension

Summary: the beach chair position for shoulder operation induces hypotension during general anesthesia. hypotension is induced by decreased preload and contractility due to anesthesia. masimo is a pulse oximetry which shows pleth variability index noninvasively. the pleth variability may predict the hypotension during beach chair position.

the beach chair position for shoulder operation induces hypotension during general anesthesia. hypotension is induced by decreased preload and contractility due to anesthesia. masimo is a pulse oximetry which shows pleth variability index noninvasively. the investigators put the masimo probe before general anesthesia and recorded the values before and after beach chair position, the values include arterial pressure, heart rate, blood pressure, perfusion index, pleth variability index. the primary end point was the predictive value and threshold or pleth variability index for hypotension induced by the beach chair position. the occurrence of hypotension was counted by using vasopressor. the use of vasopressor was performed when mean blood pressure less than 65 mmhg or 20% of baseline. the investigators planned to recruit 57 patients.

Eligibility criteria:
inclusion criteria: * elective shoulder surgery under general anesthesia exclusion criteria: * right heart failure * morbid obesity (bmi \> 30) * arrhythmia on preoperative electrocardiography * pulmonary hypertension * peripheral vascular disease or pulmonary disease * pregnant
plasma resuscitation without lung injury

Conditions: Burns

Summary: the treatment of patients with major burns requires resuscitation with massive amounts of fluid, typically a type of salt water that is given by vein. this frequently results in injury to vital organs, especially the lungs and kidneys, and even in death. in this study, the investigators propose to use plasma, a specially prepared blood product made from the liquid part of blood, that has undergone special treatment to reduce the risk of disease transmission. the aims include 1) reduce the amount of fluid given during the first 24 hours after a burn 2) reduce the incidence of lung injury and other complications related to the administration of funds and 3) determine if the blood product has any effect on inflammation. an overall decrease the amount of fluids that burn patients receive should decrease the potential for lung injury, decrease days in the hospital, and improve survival.


Eligibility criteria:
inclusion criteria: * age \> 18 years * weight \> 40 kg * initial assessment of thermal injury size ≥ 20% tbsa * admitted to the burn center and enroll able within 8 hours of injury * expected to receive intravenous resuscitation fluids for at least 24 hours after injury * expected to live \> 24 hours after injury exclusion criteria: * chemical injury * deep electric injury * associated non-thermal injuries with estimated injury severity score \> 25 * inability to obtain informed consent * decision not to treat due to injury severity or other factors * patient age \> 65 years or \< 18 years * presence of anoxic brain injury that is not expected to result in complete recover * patent already receiving plasma infusion, or judged to be likely to require plasma infusion * patent already receiving "rescue procedures" (albumin infusion, crrt, tpe, or high-dose ascorbic acid) * existence of pre-morbid conditions: congestive heart failure (nyha class iv); end-stage kidney disease (dialysis patient); cirrhosis of the liver; oxygen-dependent chronic obstructive pulmonary disease; malignancy currently under treatment; previous bilateral lower extremity amputations
cognitive ability training in seniors

Conditions: Mild Cognitive Impairment

Summary: this study investigates the beneficial effects of prefrontal brain stimulation (with transcranial direct current stimulation \[tdcs\]) during working memory training in seniors with subjective memory impairments.the placebo-controlled double blinded study includes 50 elderly probands which were randomized into verum or sham tdcs.


Eligibility criteria:
inclusion criteria: * native german speaker * between 60-70 years old * subjective memory impairment exclusion criteria: * psychiatric, neurological diseases * uncorrected hearing or vision deficits * actual psychopharmaco intake * metal parts in the head * medical electronical implants

Keywords: subjective memory impairment tdcs nirs cognitive training working memory
systemic antitumor treatment with or without pressurized intraperitoneal aerosol chemotherapy for colon peritoneal metastases (pipox02)

Conditions: Peritoneal Metastases from Colorectal Cancer

Summary: the goal of this clinical trial is to learn if pressurized intraperitoneal aerosol chemotherapy (pipac) significantly improve the progression-free survival (pfs) in patients with advanced peritoneal metastasis from colorectal cancer. researchers will compare 2 strategies, systemic treatments (chemotherapy + targeted therapy) corresponding to standard treatment with or without intraperitoneal oxaliplatin (pipac) to see if pipac improve the progression-free survival. participants will: * receive a standard treatment every 2 weeks for 12 cycles of intravenous folfiri or folfirinox + targeted systemic therapy (anti-egfr or anti-vegf) in the both arms. * receive up to a maximum of 4 pipac every 6 weeks with pressurized aerosol containing oxaliplatin in experimental arm. * receive a maintenance treatment until progression or until the onset of severe toxicity after 12 cycles. * be asked to perform a ct scan and carcinoembryonic antigen (cea) assay every 8 weeks until progression


Eligibility criteria:
inclusion criteria: * ecog performance status of 0 to 2; * histopathologically confirmed colonic adenocarcinoma with synchronous or metachronous peritoneal metastasis (pm); * unresectable pm defined as any of the following: * pci \>15 * extended small bowell involvement * poor general condition contra-indication to a major abdominal surgery (eg: a complete cytoreductive surgery), as decided by the medico-surgical team of the investigator's site specialised in peritoneal carcinomatosis in charge of the patient. * a surgical exploration performed less than 4 weeks before inclusion (if not, a laparoscopic exploration must be performed); * first line systemic chemotherapy for advanced / metastatic colonic adenocarcinoma. systemic chemotherapy in an adjuvant setting is allowed if completed more than 6 months before recurrence and without persistent oxaliplatin-induced neuropathy; * no extended intraperitoneal adherences defined by at least 9 out of 13 abdominal regions correctly explored during surgical exploration (laparoscopy or laparotomy; exclusion criteria: * other cancer treated within the last 3 years, with the exception of in situ cervical carcinoma or basocellular carcinoma; * rectal cancer primary (tumor \<15 cm from the anal verge); * mutational status corresponding to microsatellite instability high (msi-h) or mismatch repair deficient (dmmr); * complete or partial bowel obstruction unresponsive to medical treatment; * extraperitoneal polymetastatic diseases. (only oligometastatic1 diseases are allowed for inclusion); * history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess within 6 months prior to enrolment; * active gastrointestinal bleeding; * inflammatory bowel disease; * peripheral neuropathy according to the common toxicity criteria for adverse events (ctcae) version 5.0, grade ≥2

Keywords: surgical oncology peritoneal metastasis pressurized intraperitoneal aerosol chemotherapy systemic chemotherapy
study on the efficacy and safety of fecal microbiota transplantation in the treatment of steroid - dependent /steroid-resistant nephrotic syndrome in children

Conditions: Steroid-Resistant Nephrotic Syndrome; Steroid-Dependent Nephrotic Syndrome

Summary: the objective of this clinical trial was to understand whether fmt is effective in treating steroid-dependent/steroid-resistant nephrotic syndrome in children. it will also learn about the safety of fmt. the main question it was designed to answer was: did fmt reduce participants '24-hour urine protein content? what medical problems did participants experience while using fmt? the researchers will compare fmt treatment with and without fmt on top of conventional treatment to see if fmt is effective in treating steroid-dependent/steroid-resistant nephrotic syndrome in children. participants will receive 2 fmt treatments, 1 endoscopic injection under anesthesia, 1 oral fecal bacteria transplantation capsule intake, and follow-up visits (weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48) every 4 weeks from the beginning of medication to our renal specialist clinic for drug efficacy evaluation and safety testing. blood and fecal samples were collected to determine the effects of fecal bacterial transplantation on intestinal flora, fecal metabolomics, and intestinal mucosal permeability.


Eligibility criteria:
inclusion criteria: * age 2-18 years, steroid-dependent/steroid-resistant nephrotic syndrome, regardless of gender, with sdns at steroid-dependent doses less than 0.5 mg/kg.d exclusion criteria: * those with concurrent infections or diseases of other organ systems, and those with abnormal renal function.